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this techniques is not well established. We sought to assess the long-term effects of
intrarterial infusion of BMMC in patients with CLI.
Methods: from September 2004 to December 2007 intrarterial infusion of BMMC was
performed in 28 subjects with CLI (fontain grade 3 and 4, 17 men and 11 women). The
mean age was 60 years. 50% of subject in the study population had ischemic defects in
the Lower limb, 53.5% diabetes mellitus, 42.8% ischemic heart disease, 67.8% arterial
hypertension, 21.4% thrombangitis obliterans and 50% hyperlipoproteinemia.
Results: Major amputation was performed during follow up in 2 subjects 3 months after
BMMC implantation. 11 of the 14 fourteen subject with defect had healed (79%) and the
Fontaine grade improved to grade 2B in 22 subjects (84.6%). In 2 patients (7.6%) resting
pain remained in spite of defects healing but were well controlled with analgesics. In 2
subjects the size of the defect was reduced one year after BMMC treatment but did not
heal. The mean ankle brachial index was improved with treatment (0.54 vs 0.67, p
0.0001) and the mean tpO2 was improved (14.9 vs 37.2 mmHg, p 0.0001). The
overall quality of life assessed using SF-36 questionnaire was also dramatically improved
after one year (p 0.0001).After 5 years of follow up 14 patients had died (50%) due to
multiple cardiovascular comorbidities. 11 individual (39%) were without resting pain and
in the fontain class 2B. 3 patients (10%) were asymptomatic. None of the patient in the
surviving group underwent major amputation or had ischemic defect.
Conclusions: Transcatheter intra-arterial administration of BMMC is a suitable alterna-
tive for treatment of patients with critical limb ischemia. However, the midterm benefits
of this method are limited by long term unfavorable outcome due to high mortality caused
by cardiovascular comorbidities
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Background: Distal embolization (DE) events are commonly reported in percutaneous
atherectomy procedures. Embolic protection (EP) devices reduce these events. This study
compared inpatient hospital costs and resource utilization in two non-coronary (presumed
lower extremity) atherectomy patient populations: (1) a DE event group, and (2) an EP
group.
Methods: All inpatient discharges for atherectomy of non-coronary vessels (ICD-9-CM
procedure code 39.50) were selected from a comprehensive hospital admissions database
(Premier Perspective CY2005-20 10). DE patients were identified using ICD-9-CM
diagnosis codes (444.XX, 434.0, and 434.1). Patients receiving EP devices were identified
using a billing data keyword search. Discharges in the DE and EP groups were propensity
matched adjusting for age, gender, race and severity scores. Inpatient mortality, length of
stay, operating room (OR) time, and costs were compared between the groups.
Results: After propensity matching DE and EP groups, there were n1,497 matched
pairs. The inpatient mortality rate was significantly higher in DE compared to EP (2.7%
vs. 1.3%, p0.05). Hospital stay averaged 1.4 days longer in the DE patients (p0.05).
Room and board, surgery and pharmacy costs were significantly higher for DE (p0.05).
OR time was 24 minutes longer for DE patients. Total costs were higher but not
significant for the DE group ($24,326 vs. $23,594, p0.38). As a reference, the total rate
of embolic events detected in this inpatient population was 13.5 percent.
Conclusions: The use of embolic protection is strongly associated with lower inpatient
mortality rates, shorter hospital stays, and shorter OR times. Cumulatively, these findings
demonstrate embolic protection devices may significantly reduce consumption of hospital
resources.
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Background: Recent registries and randomized trials support the role of percutaneous
revascularization in patients with critical limb ischemia (CLI) and life limiting claudica-
tion (LLC) due also to infragenicular atherosclerotic disease. However, the percutaneous
transluminal angioplasty (PTA) may result in high restenosis rate and target lesion
revascularization.Promising results are coming from ond randomised controlled study an
single center registries using drug eluting balloon (DEB) in this arterial district.
Methods: Between December 2008 and December 2010, 75 (48 males) consecutive
patients underwent percutaneous revascularization of below the knee(BTK) arteries in our
institution due to CLI(58[72.5%]) and LLC(17[27.5%]). Functional status was Rutheford
class 3 in 4 (5%) patients, class 4 in 24(30%) patients, class 5 in 37(50%), and class 6 in
10(15%). All patients(98 lesions) were treated predilating with an undersized standard
balloon and then with Pacltaxel Eluting Balloon In.Pact Amphirion (Medtronic).No
limitation in number of vessels treated, lesion length were considered (mean treated length
8925 mm). A total occlusion was the target lesion in 47% of cases. In 22 cases above
the knee arteries were previously treated.Polpliteal artery was the target lesion in 17 cases,
anterior tibial artery in 28 cases, posterior tibial artery in 23 cases, peroneal artery in 16
cases.
Results: Procedural success, meaning angiographic evidence of restored antegrade flow,
was achieved in 70 (94%) patients. Bail-out stenting for flow limiting dissection or abrupt
target vessel occlusion was needed in 7 patients(10%). Procedural complication:distal
embolization 2(2.5%),access site complication 1(1.5%), intra-hospital mortality
1(1,5%).The rate of angiographic restenosis at twelve months was 24% (n15). Only
symptomatic patients were planned for a reintervention(n9). One-year primary patency
was 76%(n52); secondary patency was 91% (n61).
Conclusions: The outcome of this single center experience suggest that the use of drug
eluting balloon for percutaneous transluminal angioplasty of below the knee arterial
lesions is feasible, safe, and provides favourable one-year clinical results in patients with
CLI.
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Background: Drug eluting stents (DES) have become the standard therapy for coronary
interventions, however its benefits on peripheral artery disease are not as clear, particularly
in below-knee peripheral arterial disease.
Methods: All randomized controlled trials of drug eluting stents in below-knee peripheral
artery disease were sought in PubMed, and Cochrane databases during May 2012. Data
was extracted by 3 reviewers and analyzed with RevMan 5.1 software.
Results: Four randomized controlled trials were found. Our analysis demonstrated a clear
benefit in patency manifested by a freedom of target lesion revascularization up to four
times higher with DES (p0.001, Figure1) and an improvement of at least one level on
the Rutherford classification up to two times higher at 6 to 12 months (p0.005, Figure
2). There was a non significant trend favoring DES in reducing major amputations (Figure
3) and death incidence was similar.
Conclusions: Our meta-analysis shows that DES significantly improves patency and
symptoms when compared to BMS for the revascularization of below-knee arterial
disease.
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Background: Peripheral interventional therapy to treat occlusive disease for patients
with symptomatic claudication is considered standard clinical practice. The present study
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Peripheral Vascular Disease and Intervention B47
P
O
ST
E
R
S
